Language:
Instant News and Commentaries
2026-11-20
13:05
Trip.Best Unveils Its Biggest Global Rankings Yet, Covering All Seven Continents for the First Time

Global travel rankings grow to 98 annual lists across nine regions and 22 languages, with the first standalone Oceania lists.

SYDNEY, Nov. 20, 2026 /PRNewswire/ -- Trip.Best, the global travel rankings from Trip.com Group, launched its 2027 Annual Rankings in Sydney, extending coverage to all seven continents for the first time. Unveiled at The Dome, Sydney Showground, as part of Trip.com Group's Global Partner Summit, this year's edition grows from 85 to 98 annual rankings and from five to nine regions, across 22 languages.

Oceania, Africa and Antarctica join as new regions, and the Americas are now split into North and South America. In total, the 2027 Annual Rankings feature more than 3,700 entries across 112 countries and regions, spanning hotels, attractions, nightlife, dining and destinations. Winners were recognised at the Global 100 Awards Ceremony.

Oceania Steps Into the Global Spotlight With Eight Standalone Rankings

Oceania Steps Into the Global Spotlight With Eight Standalone Rankings
Oceania Steps Into the Global Spotlight With Eight Standalone Rankings

For the first time, Trip.Best publishes eight standalone Oceania 50 lists, recognising more than 250 hotels, attractions, restaurants and experiences across Australia, New Zealand and the Pacific islands. The lists cover scenic hotels, must-see and family attractions, nightlife, fine dining and must-visit restaurants, with ski-resort and hot-spring rankings reflecting the region's year-round appeal.

Top-ranked winners include:

  • Scenic Hotel: Four Seasons Resort Bora Bora, followed by Park Hyatt Sydney and Rosewood Kauri Cliffs in New Zealand.
  • Best Things to Do: Sydney Opera House, followed by Bora Bora and the TSS Earnslaw Steamship in Queenstown.
  • Fine Dining: Essence in Queenstown, followed by Bennelong in Sydney and Jano Bistro in Wellington.
  • Must-Visit Restaurant: Fergburger in Queenstown, followed by Bar Totti's in Sydney and Depot in Auckland.

Global 100 Lists Honour Leading Hotels, Sights and Restaurants

Global 100 Lists Honour Leading Hotels, Sights and Restaurants
Global 100 Lists Honour Leading Hotels, Sights and Restaurants

At global level, the Global 100 lists are led by:

  • Luxury Hotel: Hôtel de Crillon, A Rosewood Hotel in Paris, followed by Raffles Singapore and Le Bristol Paris.
  • Scenic Hotel: Il San Pietro di Positano in Italy, followed by Cheval Blanc Randheli in the Maldives and Le Sirenuse in Positano.
  • Best Things to Do: The Louvre in Paris.
  • Fine Dining: DiverXO in Madrid, followed by L'Arpège in Paris and Disfrutar in Barcelona.

New Wonders Lists Showcase What Makes a Destination Distinctive

New Wonders Lists Showcase What Makes a Destination Distinctive
New Wonders Lists Showcase What Makes a Destination Distinctive

Trip.Best also introduces Wonders - a new collection of rankings aimed at international travellers seeking inspiration for their next destination. Each list is built on what makes a destination distinctive and what gives it an edge over others across markets. The collection comprises 49 themed lists across 10 countries and four categories (hotels, attractions, food and destinations) and is available in 22 languages.

Australia features in two lists: Native Wildlife Conservation Encounters, led by Currumbin Wildlife Sanctuary, and Outdoor Adventures, led by Cairns. Global Wonders lists include Diving Experiences, Ski Towns and Sunset Views.

About Trip.com Group

Trip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com. Follow us on: X, Facebook, LinkedIn, and YouTube.

Information Provided by PR Newswire [Disclaimer]
13:00
Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

SHANGHAI, Nov. 20, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).

ASCEND's primary efficacy endpoint is the change in best-corrected visual acuity (BCVA) from baseline to Week 36 versus aflibercept dosed every eight weeks. The goal of the ASCEND study is to determine the dose(s) to advance into VIS-101's global Phase 3 program based on safety, efficacy and durability.

VIS-101 is a purpose-designed tetravalent, dual VEGF-A x ANG-2 inhibitor in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.

Wet AMD affects more than 20 million people globally[1]. In China, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment.

"Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101. With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control. ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.

Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients."

On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.

About the ASCEND Phase 2b Trial

ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b study (NCT07798375) to evaluate the safety and efficacy of VIS-101 (aka AM712 or ASKG712) in approximately 244 treatment naïve patients with wet AMD in China. Patients will be randomized to either 6 mg or 9 mg VIS-101, or 2 mg aflibercept, a standard-of-care anti-VEGF therapy. All patients will initially receive three monthly doses of either VIS-101 or aflibercept and can then be retreated based on protocol-specified retreatment criteria that are the same for all groups up to Month 9. The main objectives are to determine the dose(s) to be studied in Phase 3 clinical trials and establish the initial durability with treatment intervals up to seven months after three loading doses.

About VIS-101

VIS-101 (also known as ASKG712 or AM712), is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101's bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity and avidity, for rapid, robust and durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is currently being evaluated in the dose-determining Phase 2b ASCEND study, with initiation of the global Phase 3 program planned as early as 2027.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.

Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.

For more information, please visit the Company's website: www.everestmedicines.com. 

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Source information:

  1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26

Information Provided by PR Newswire [Disclaimer]
12:59
雲頂新耀宣佈VIS-101治療濕性AMD的IIb期ASCEND臨床研究完成首例患者給藥

上海2026年11月20日 /美通社/ -- 雲頂新耀(HKEX 1952.HK),是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司,宣佈VIS-101治療濕性年齡相關性黃斑變性(濕性AMD)的IIb期ASCEND臨床研究已完成首例患者給藥。

ASCEND研究是一項隨機IIb期臨床研究,旨在綜合評估VIS-101的安全性、療效及療效持久性,確定後續全球III期臨床開發所採用的劑量。該研究計劃在中國納入244例未接受過治療的濕性AMD患者,設置VIS-101 6 mg和9 mg兩個劑量組,並以阿柏西普2 mg(每8周給藥一次)作為活性對照。主要療效終點為第36周時最佳矯正視力(BCVA)相較基線的變化。

在此前一項隨機、劑量探索性IIa期臨床研究中,VIS-101在濕性AMD患者中展示出起效迅速、強效持久的治療反應,及良好的安全性及耐受性。其中,6 mg 組中約半數初治受試者在第36周前無需補救治療。

VIS-101作為一款靶向VEGF-A和ANG-2的新型四價雙特異性抗體,具備同類最佳潛力,有望為濕性AMD患者帶來新的治療選擇,並展現出在糖尿病性黃斑水腫(DME)、視網膜靜脈阻塞(RVO)等其他視網膜血管疾病領域進一步探索的前景。

濕性AMD等視網膜血管疾病患者群體龐大,目前全球有超過2,000萬濕性AMD患者[1]。在中國,濕性AMD和DME的現有及新增患者人數已超過1,500萬,每年新增約60萬例,而目前接受抗VEGF治療的患者人數僅約50萬,存在巨大的臨床需求。

雲頂新耀首席執行官羅永慶表示:「濕性AMD等視網膜血管疾病患者群體龐大,不僅影響患者視力和生活質量,也帶來長期疾病負擔,患者對更優治療方案的需求尚未得到充分滿足。VIS-101在治療濕性AMD的IIa期臨床研究中展示出起效迅速、強效持久的治療反應,同時安全性和耐受性良好。

IIb期ASCEND臨床研究完成首例患者給藥,是VIS-101臨床開發中的重要進展。該研究以現有標準療法為對照,將進一步評估VIS-101的療效、安全性及持久性,重點探索其延長給藥間隔、實現持久疾病控制的潛力,並為後續全球臨床開發提供重要依據。眼科是雲頂新耀聚焦的核心治療領域之一,憑借在中國和亞洲市場的深厚積累,我們將加快推進VIS-101的臨床開發進程,讓這款創新療法惠及更多患者。」

關於IIb期ASCEND臨床研究

ASCEND是一項隨機、四重盲法、陽性藥物對照的頭對頭IIb期臨床研究(NCT07798375),旨在評估VIS-101(又稱AM712或ASKG712)在中國約244例未經治療的濕性年齡相關性黃斑變性(濕性AMD)患者中的安全性和有效性。

研究將患者隨機分配至VIS-101 6 mg組、VIS-101 9 mg組或阿柏西普(aflibercept)2 mg組。阿柏西普是一種抗VEGF標準治療藥物。所有患者首先接受連續三個月、每月一次的VIS-101或阿柏西普治療,隨後根據研究方案預設的再治療標準決定後續給藥。直至第9個月,各治療組均採用相同的再治療標準。

本研究旨在確定適用於III期臨床試驗的VIS-101劑量,並初步評估其給藥持久性,探索在完成三次負荷給藥後最長可達七個月的給藥間隔。

關於VIS-101

VIS-101(又名ASKG712或AM712)是一款靶向 VEGF-A/Ang-2的新型雙特異性融合蛋白,具備同類最佳潛力,擬用於治療濕性年齡相關性黃斑變性(濕性AMD)、糖尿病性黃斑水腫(DME)、視網膜靜脈阻塞(RVO)。其雙特異性、四價結構擁有更多結合位點,對VEGF-A 和ANG-2的親和力與結合力更強,可帶來起效迅速、強效持久的治療應答。目前VIS-101已在美國和中國完成初步安全性及劑量遞增研究,並在中國完成隨機、劑量探索IIa期研究(NCT05456828),IIb期ASCEND臨床研究正在積極推進中,全球III期臨床研究最早於2027年啟動。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司,致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地,並依據中國、歐盟和WHO標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM(心血管、腎臟及代謝)等疾病治療領域,已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台。公司已建立涵蓋藥品生產製造、經營流通及商業化運營的業務體系,並具備相應的藥品生產和經營資質,進一步完善了從生產端到市場端的業務佈局,為藥品供應、分銷及商業化業務的持續拓展提供支持。

同時,公司依托擁有全球權益的自研mRNA平台為基礎,持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線,同時通過引進及生態孵化潛力平台,拓展研發能力,同時強化全球化佈局,加快國際化發展進程。

更多信息,請訪問公司官網:www.everestmedicines.com。

前瞻性聲明

本新聞稿所發佈的信息中可能會包含某些前瞻性表述,乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期,可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證,會受到風險、不確定性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響,實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務,除非法律要求。

參考文獻

1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62(14): 26. doi: 10.1167/iovs.62.14.26

Information Provided by PR Newswire [Disclaimer]
12:05
IMF Managing Director: AI Investment Adjustment Not Yet Over

Concerns over returns on AI investment intensified global market volatility. International Monetary Fund (IMF) Managing Director Kristalina Georgieva said the IMF had previously expected an adjustment in AI-related capital markets due to overheated market sentiment, but no major correction has emerged so far and she believed more market adjustments will come in the future.

According to the IMF's conservative estimates, AI could contribute 0.5 ppts to global economic growth, Georgieva said, adding that this year marks the first time in history that AI has had a substantive impact on global economic growth.

When asked about the economic impact of US restrictions on chip exports to SE Asian countries, she said the threat is not enormous at present. However, the greater risk would be technological fragmentation forcing countries to choose sides, which could lead to more serious consequences.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
10:40
Anthropic Debut Ends Up 17%; NVIDIA Slides 40% from Peak in Over a Mth

Anthropic, PBC (ANT.US) priced its IPO at USD83 per share, valuing the developer of chatbot Claude at about USD1.5 trillion. The market is keeping a close tab as to whether its first trading day performance can create a more optimistic atmosphere on Wall Street than the earnings released by NVIDIA (NVDA.US). Anthropic shares closed at USD97.17 on Thursday (19th), up 17.1% from the IPO price.

NVIDIA reported strong results this week, including quarterly sales guidance of USD130 billion. However, the stock still closed down 3.3% on Thursday (19th), about 40% below the record peak reached in early October. Market participants expected strong demand for Anthropic shares to help revive sentiment toward tech stocks.

The market stayed positive on Anthropic's first trading day prospects, particularly for tech stocks. Goldman Sachs European equities trading head Rich Privorotsky said "today feels important".

The AI industry remains highly vibrant. Google is launching a multi-million-dollar project to melt rocks near a volcano in Oregon in an attempt to create clean energy supplies for its data centers.

Federal Reserve Governor Christopher Waller said the central bank may need to shock market participants to break inflation expectations, which could require more than three interest rate hikes.

A series of major technology outages over the past week has prompted lawmakers in Washington to seek answers. Meanwhile, hedge fund Bridgewater Associates said a specific inflection point for exponential growth in cyber incidents has already emerged.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:09
US Approves Shipment of ~900,000 Advanced AI Chips to CN within 6 Mths; TENCENT Receives 150,000 Units, BABA-W Gets 75,000

The US House Foreign Affairs Committee said the US government approved the shipment of nearly 900,000 advanced AI chips manufactured by NVIDIA (NVDA.US) and Advanced Micro Devices (AMD.US) to Chinese companies between December 2025 and May 2026.

Among them, 75,000 units were shipped to BABA-W (09988.HK), 150,000 units to TENCENT (00700.HK), 43,000 units to BIDU-W (09888.HK), and 4,000 units to BYD COMPANY (01211.HK). The above companies have all been included on the Pentagon's list of firms allegedly linked to the Chinese military.

Multiple companies applied during the period for approval to ship more than 3.4 million chips to China, documents showed. It remains unclear how many of the approved chips were ultimately delivered to China. The chips involved included NVIDIA's H200 and AMD's equivalent MI325X chips.

NVIDIA said in a statement that the approvals were subject to strict conditions and limited quantities. Although export licenses were granted, the company has stopped shipping H200 chips to China. AMD said it complies with applicable US export control laws and regulations and maintains strict procedures to ensure compliance across its global operations.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:06
NVIDIA Shrs Slump for 6 Straight Days; Mkt Cap Wipes off by USD600B+

NVIDIA (NVDA.US) shares elevated in early trading on Thursday, partly propelled by optimism surrounding Anthropic's IPO, but turned lower again by midday. The stock closed at USD145.98 last night, down 3.3%. The company's market cap has wiped off by more than USD600 billion over the past six trading days.

Analysts said multiple factors are weighing on the stock, including Moody's decision on Wednesday to revise NVIDIA's outlook from Positive to Stable.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
08:59
California Attorney General Issues Subpoena to NVIDIA Over Probe Into CN Chip Diversion

The office of California Attorney General Rob Bonta said Bonta on Thursday issued an investigative subpoena to NVIDIA (NVDA.US) as part of a probe into whether the company's advanced semiconductor chips ultimately flowed into China in violation of US export restrictions.

The investigation was launched one week after former NVIDIA CEO Jensen Huang resigned over allegations involving multiple extramarital affairs, including accusations related to Alice Huang, who is suspected of being a Chinese spy. Alice Huang previously worked at Singapore-based Megaspeed, which is under investigation for potentially transshipping restricted NVIDIA chips to China.

Bonta said in a statement that the conduct of NVIDIA and its former CEO raises significant red flags, including how the company may have misled investors. The office is investigating whether actions by NVIDIA or Jensen Huang enabled China to obtain advanced chips or confidential information, and whether NVIDIA misled investors and the public regarding such risks in violation of the law.

NVIDIA did not immediately respond to requests for comment regarding Bonta's subpoena.

NVIDIA shares have nosedived 22% over the nine trading days since Jensen Huang admitted to extramarital affairs. The stock is on track for a seventh consecutive weekly decline, with total losses of 38% during the period.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
08:58
CATL Opens Türkiye's First NING SERVICE Experience Center in Istanbul

ISTANBUL, Türkiye, Nov. 20, 2026 /PRNewswire/ -- CATL today announced the official launch of its first NING SERVICE Experience Center in Türkiye. The facility serves as the country's first dedicated battery depot repair center and integrated sales-and-service hub, marking a further step in expanding its localized new energy aftermarket service network and supporting the country's shift towards cleaner energy systems.


Türkiye sits at the crossroads of Europe, Asia and the Middle East — a regional economic hub with a fast-growing EV market and a rapidly expanding energy storage sector, where the shift toward clean energy is driving demand for specialized battery support. Its National Energy 2040 plan targets 20 million electric vehicles and 140 GWh of storage requirement by 2040. Against that backdrop, NING SERVICE is delivering full-lifecycle battery services on both the road and the grid, reinforcing the infrastructure that transition depends on.

Located in Istanbul, the NING SERVICE Experience Center represents an important milestone in the collaboration between CATL and Ascendum Türkiye, part of Ascendum Group, offering comprehensive full-lifecycle after-sales support, cultivating local technical talent and accelerating the deployment of advanced electrification and energy storage solutions. 

Covering more than 1,200 square meters, the Istanbul center brings together service zones for battery testing, diagnosis, repair, maintenance and refurbishment, exhibition and retail space, training rooms and a customer lounge. The exhibition and retail area presents CATL's system-level capabilities across electric mobility and energy storage, including bedrock chassis, portable power stations, battery protection plates and integrated charging-and-storage units. The center serves as a localized service hub for the region and as a platform connecting partners across the ecosystem.

Providing a comprehensive new energy aftermarket service system

As CATL's independent aftermarket service brand, NING SERVICE delivers a one-stop, full-lifecycle battery service system that encompass battery diagnostics, repair, maintenance, refurbishment, training, recycling, aftermarket logistics and warehousing. Backed by CATL's deep R&D and extreme manufacturing capabilities, its services product categories from passenger and commercial vehicles to energy storage systems, setting a new benchmark for new energy service delivery in the region.

That capability is delivered through one of the industry's largest after-sales networks:

  • 1,429 professional service locations across more than 80 countries and regions, with the aim of reaching 100 countries and regions by 2027 and 10,000 service locations by 2030;
  • More than 9,900 service engineers and over 10,000 technicians certified for new energy after-sales service, with a 24-hour response mechanism in overseas markets;
  • Its deep-repair capability, delivered through a network of 95 centers, covers 76.8% of EV models and 90% of repair jobs;
  • The Intelligent Eagle Eye System, in use at more than 150 repair facilities, providing full traceability and quality control;
  • The Intelligent Battery Check System, supporting precise battery health diagnostics, slows battery aging by up to 9.5%;
  • More than 70 industry standards participated in or revised, and over 200 authorized patents worldwide

Strengthening local partnerships and service capabilities

CATL is extending its local footprint by strengthening infrastructure and building partnerships in the market. By combining CATL's technological expertise with Ascendum Group's 67 years of industrial heritage and robust local network, the Istanbul center enables CATL to serve clients throughout Türkiye, putting its know-how and rapid-response capability close to where batteries are actually in use.

The center anchors a network to all Türkiye and a team of CATL-certified engineers. It also serves as the network's training base, where technicians are trained and certified to CATL's standards before they work on customer batteries, building a local pool of battery service skills that the market will keep drawing on.

"The opening of Türkiye's first NING SERVICE Experience Center marks an important milestone in our strategic partnership with CATL and represents the first business initiative launched under Ascendum Green.Shift," said Tolga Polat, CEO of Ascendum Türkiye. "By combining CATL's advanced battery technologies with Ascendum's long-standing technical service expertise and customer-focused approach, we aim to provide reliable, high-quality aftermarket solutions across Türkiye. We are investing in local technical capabilities, developing specialized teams and strengthening our service infrastructure to meet the evolving needs of the energy and mobility sectors. Looking ahead, our goal is to gradually expand our service network nationwide and build a sustainable ecosystem that creates long-term value for our customers and supports Türkiye's energy transition."

"Türkiye has moved into the fast lane on electrification, and demand for aftermarket service will grow with it," said Bruce Li, Co-president of Sales & Marketing and President of Commercial Applications & Aftermarket Business of CATL. "As our first NING SERVICE Experience Center in the country, it brings CATL's technology, our training standards and Ascendum's local reach together, so that customers on the road and on the grid are served by people and parts that are already here. From here, we will keep extending our service network across Türkiye, work in step with the country's National Energy 2040 goals, and give the energy transition the service backbone it needs to hold up over time." 


Looking ahead, NING SERVICE will continue to drive innovation in maintenance technology, service models and network expansion. The Istanbul center is the first step in Türkiye, with further network build-out and capability development to follow.

 

Information Provided by PR Newswire [Disclaimer]
2026-11-19
18:00
Trip.com Group Limited to Report Third Quarter of 2026 Financial Results on December 1, 2026 U.S. Time

SINGAPORE, Nov. 19, 2026 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its financial results for the three months ended September 30, 2026 on Tuesday, December 1, 2026, U.S. Time, after the market closes.

Trip.com Group's management team will host a conference call at 7:00 PM U.S. Eastern Time on December 1, 2026 (or 8:00 AM on December 2, 2026 in the Hong Kong Time) following the announcement.

The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived for twelve months at this website.

All participants must pre-register to join this conference call using the Participant Registration link below:
https://register-conf.media-server.com/register/BI709a150ad7f14478b5e6a4b0f8ae0e9f.

Upon registration, each participant will receive details for this conference call, including dial-in numbers and a unique access PIN. To join the conference, please dial the number provided, enter your PIN, and you will join the conference instantly.

About Trip.com Group Limited

Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for many travelers in Asia, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com and Skyscanner, with the mission "to pursue the perfect trip for a better world."

For further information, please contact:

Investor Relations
Trip.com Group Limited
Email: [email protected]

Information Provided by PR Newswire [Disclaimer]